Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bure Equity AB ( (SE:BURE) ) just unveiled an update.
Bure Equity AB reported a sharp deterioration in 2025, with net asset value per share falling 19.8% to SEK 267.2 and total shareholder return at -34.8%, significantly underperforming the SIX Return Index. Group earnings swung to a loss of SEK 4,676M, driven mainly by steep share price declines in key portfolio holdings such as Yubico, Xvivo, and Vitrolife, whose growth and profitability lagged market expectations.
Operational performance across the portfolio was mixed: Mycronic delivered strong growth and profit, while Vitrolife, Yubico, and Xvivo faced weaker demand and margin pressure. Bure reshaped its portfolio by acquiring a 17% stake in MEMS foundry leader Silex Microsystems for SEK 900M and funding this partly through divestments in Ovzon, Mycronic, and the full exit from Mentice, while also subscribing to BioLamina convertibles and continuing to fine-tune holdings.
After the balance sheet date, net asset value per share declined further to SEK 233.0 by 18 February 2026, even as Bure continued to sell down Ovzon and proposed maintaining an ordinary dividend of SEK 2.75 per share. CEO Henrik Blomquist highlighted a tough market environment marked by currency headwinds, revaluation of growth stocks, and geopolitical uncertainty, but reaffirmed confidence in the portfolio’s long-term quality and emphasised near-term focus on improving profitability and positioning for future growth.
The most recent analyst rating on (SE:BURE) stock is a Hold with a SEK215.00 price target. To see the full list of analyst forecasts on Bure Equity AB stock, see the SE:BURE Stock Forecast page.
More about Bure Equity AB
Bure Equity AB is a Swedish investment company focused on export-oriented, fast-growing technology businesses, including listed and unlisted holdings in sectors such as semiconductors, life science, and digital services. Its portfolio includes companies like Yubico, Xvivo, Vitrolife, Mycronic, Mentimeter, and Silex Microsystems, with an active ownership approach and long-term value creation focus.
Average Trading Volume: 97,629
Technical Sentiment Signal: Sell
Current Market Cap: SEK14.3B
For detailed information about BURE stock, go to TipRanks’ Stock Analysis page.